Pfizer Inc
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Remaining Performance Obligations (RPO) by Quarter
Remaining Performance Obligations (RPO) — Comirnaty multi-year contracts ($M) ($M)
Pfizer Remaining Performance Obligations (RPO): $2,000M in Q2 2026, down 50.0% from a year earlier. That is the lowest of the 11 quarters on record here.
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-04) ↗
Reported in Form 10-Q / 10-K Revenue Note.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Remaining Performance Obligations (RPO) — Comirnaty multi-year contracts ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 28, 2026 | 2,000 | -50.0% | Form 10-Q (filed 2026-08-04) ↗ |
| Q1 2026 | Mar 29, 2026 | 2,100 | -30.0% | Form 10-Q (filed 2026-05-05) ↗ |
| Q4 2025 | Dec 31, 2025 | 2,100 | -47.5% | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2025 | Sep 28, 2025 | 3,000 | -50.0% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2025 | Jun 29, 2025 | 4,000 | -33.3% | Form 10-Q (filed 2025-08-05) ↗ |
| Q1 2025 | Mar 30, 2025 | 3,000 | -50.0% | Form 10-Q (filed 2025-05-05) ↗ |
| Q4 2024 | Dec 31, 2024 | 4,000 | -33.3% | Form 10-K (filed 2025-02-27) ↗ |
| Q3 2024 | Sep 29, 2024 | 6,000 | – | Form 10-Q (filed 2024-11-04) ↗ |
| Q2 2024 | Jun 30, 2024 | 6,000 | – | Form 10-Q (filed 2024-08-05) ↗ |
| Q1 2024 | Mar 31, 2024 | 6,000 | – | Form 10-Q (filed 2024-05-08) ↗ |
| Q4 2023 | Dec 31, 2023 | 6,000 | – | Form 10-K (filed 2024-02-22) ↗ |
Cite this data
StockData. (2026). Pfizer Remaining Performance Obligations (RPO) ($M), quarterly Q4 2023–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/rpo-comirnaty
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.